Surveillance after treatment for cervical intraepithelial neoplasia: Outcomes, costs, and cost-effectiveness

Obstetrics and Gynecology

Volumn 116, Issue 5, 2010, Pages 1158-1170

  Melnikow, Joy ^a   Kulasingam, Shalini ^b   Slee, Christina ^b   Helms, L Jay ^b   Kuppermann, Miriam ^b   Birch, Stephen ^b   McGahan, Colleen E ^b   Coldman, Andrew ^b   Chan, Benjamin K S ^b   Sawaya, George F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL EVALUATION; COHORT ANALYSIS; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; CYTOLOGY; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPLICATION; COST BENEFIT ANALYSIS; CRYOSURGERY; CYTODIAGNOSIS; ECONOMICS; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PROBABILITY; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX CONIZATION; VIROLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CONIZATION; COST-BENEFIT ANALYSIS; CRYOSURGERY; CYTODIAGNOSIS; FALSE POSITIVE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MARKOV CHAINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 78049332021     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181f88e72     Document Type: Article

References (41)

1. Jones BA, Davey DD. Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med 2000;124:672-81.
2. Woolf T. Screening for cervical cancer. Preventing disease: Beyond the rhetoric. New York (NY): Springer Verlag; 1990. p. 319-23.
3. Melnikow J, McGahan C, Sawaya GF, Ehlen T, Coldman A. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst 2009;101:721-8.
4. Strander B, Andersson-Ellstrom A, Milsom I, Sparen P. Long term risk of invasive cancer after treatment for cervical intra-epithelial neoplasia grade 3: population based cohort study. BMJ 2007;335:1077.
5. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007;197: 340-5.
6. Management of abnormal cervical cytology and histology. ACOG Practice Bulletin No. 99. American College of Obstetricians and Gynecologists. Obstet Gynecol 2008;112: 1419-44.
7. Cervical cytology screening. ACOG Practice Bulletin No. 109. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;114:1409-20.
8. Gold M SJ, Russell L, Weinstein M. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press; 1996.
9. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 388 November 2007: supracervical hysterectomy. Obstet Gynecol 2007;110:1215-7.
10. Kuppermann M, Melnikow J, Slee C, Tancredi DJ, Kulas-ingam S, Birch S, et al. Preferences for surveillance strategies for women treated for high-grade precancerous cervical lesions. Gynecol Oncol 2010;118:108-15.
11. Canfell K, Barnabas R, Patnick J, Beral V. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer 2004;91:530-6.
12. Minino AM, Heron MP, Murphy SL, Kochanek KD. Deaths: final data for 2004. Natl Vital Stat Rep. 2007;55:1-119.
13. Keshavarz H. Hysterectomy surveillance-United States, 1994-1999. MMWR 2002; 51:1-8.
14. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillo-mavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-71.
15. National Cancer Institute. Surveillance, Epidemiology, End Results (SEER) Cancer Statistics Review, 1973-1994. NIH Publication No. 97-2789. Available at: http://seer.cancer.gov/csr/1973-1994/. Retrieved October 19, 2009.
16. Chan BK, Melnikow J, Slee CA, Arellanes R, Sawaya GF. Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review. Am J Obstet Gynecol 2009;200:422.e421-9.
17. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-101.
18. Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ 2007;335:28.
19. Cantor SB, Cardenas-Turanzas M, Cox DD, Atkinson EN, Nogueras-Gonzalez GM, Beck JR, et al. Accuracy of colpos-copy in the diagnostic setting compared with the screening setting. Obstet Gynecol 2008;111:7-14.
20. Helms LJ, Melnikow J. Determining costs of health care services for cost-effectiveness analyses: the case of cervical cancer prevention and treatment. Med Care 1999;37:652-61.
21. Hoover DR, Crystal S, Kumar R, Sambamoorthi U, Cantor JC. Medical expenditures during the last year of life: findings from the 1992-1996 Medicare current beneficiary survey. Health Serv Res 2002;37:1625-42.
22. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, et al. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007;11:201-22.
23. Centers for Medicare and Medicaid Services. 100% Medicare Provider Analysis and Review (MEDPAR). Available at: http://www.cms.hhs.gov/ MedicareFeeforSvcPartsAB/03-MEDPAR. asp. Retrieved October 19, 2009.
24. Centers for Medicare and Medicaid Services. Clinical diagnostic laboratory fee schedule files. Available at: http://www.cms. hhs.gov/ClinicalLabFeeSched. Retrieved October 19, 2009.
25. Centers for Medicare and Medicaid Service. Anesthesiologists billing and payment. Available at: http://www.cms.hhs.gov/center/anesth.asp. Retrieved October 19, 2009.
26. Centers for Medicare and Medicaid Services. National physician fee schedule relative value file. Available at: http://www. cms.hhs.gov/ PhysicianFeeSched/PFSRVF. Retrieved October 19, 2009.
27. Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. Health Serv Res 1972;7:118-33.
28. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24(Suppl 3):S3/78-89.
29. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008;111:167-77.
30. Soutter WP, Butler JS, Tipples M. The role of colposcopy in the follow up of women treated for cervical intraepithelial neoplasia. BJOG 2006;113:511-4.
31. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004;191:114-20.
32. Eggleston KS, Coker AL, Prabhu Das I, Cordray ST, Luchok KJ. Understanding barriers for adherence to follow-up care for abnormal Pap tests. J Women Health 2007;16:311-30.
33. Melnikow J, Chan BK, Stewart GK. Do follow-up recommendations for abnormal Papanicolaou smears influence patient adherence? Arch Fam Med 1999;8:510-4.
34. Alexander GC, Stafford RS. Does comparative effectiveness have a comparative edge? JAMA 2009;301:2488-90.
35. Bidus MA, Maxwell GL, Kulasingam S, Rose GS, Elkas JC, Chernofsky M, et al. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstet Gynecol. 2006;107:997-1005.
36. Cochand-Priollet B, Cartier I, de Cremoux P, Le Gales C, Ziol M, Molinie V, et al. Cost-effectiveness of liquid-based cytology with or without hybrid-capture II HPV test compared with conventional Pap smears: a study by the French Society of Clinical Cytology. Diagn Cytopathol 2005;33:338-43.
37. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62.
38. Sirovich BE, Welch HG. The frequency of Pap smear screening in the United States. J Gen Int Med 2004;19:243-50.
39. Sawaya GF, Iwaoka-Scott AY, Kim S, Wong ST, Huang AJ, Washington AE, et al. Ending cervical cancer screening: attitudes and beliefs from ethnically diverse older women. Am J Obstet Gynecol 2009;200:40.e41-7.
40. Siebers AG, Klinkhamer PJ, Grefte JM, Massuger LF, Vedder JE, Beijers-Broos A, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 2009;302: 1757-64.
41. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009;10:672-82.